ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1684 • ACR Convergence 2025

    Integration of Multiple Spatial Transcriptomics Reveals Novel Insights into Sjogren Disease Salivary Gland Fibroblast by Peripheral Serostatus

    Zhou Fang1, Ahmet Coskun1 and Sara McCoy2, 1Georgia Tech, Atlanta, 2University of Wisconsin–Madison, Madison, WI

    Background/Purpose: Anti-SSA antibody positive (SSA+ [Ro52 or Ro60]) and negative (SSA-) Sjögren disease (SjD) have differing clinical phenotypes and prognostic features; however, the pathogenesis driving…
  • Abstract Number: 1704 • ACR Convergence 2025

    Relationships between Neighborhood Disadvantage, Cumulative Social Disadvantage, and JIA Outcomes: A CARRA Registry Study

    William Soulsby1, John Boscardin2, Daniel Horton3, Andrea Knight4, Karine Toupin-April5 and Emily von Scheven2, 1University of California, San Francisco, San Francisco, CA, 2UCSF, San Francisco, CA, 3Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 4Hospital for Sick Children, Toronto, ON, Canada, 5University of Ottawa, Ottawa, ON, Canada

    Background/Purpose: Social determinants of health (SDOH) operate across individual, family, and community levels. We previously demonstrated that cumulative social disadvantage, comprised of individual and family-level…
  • Abstract Number: 1746 • ACR Convergence 2025

    Inflammatory- and Fibrosis-Related Biomarkers and Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk

    Bryant England1, Tate Johnson1, Michael Duryee1, Halie Frideres2, Katherine Wysham3, Grant Cannon4, Gary Kunkel5, Dana Ascherman6, John Richards7, Paul Monach8, Gail Kerr9, Andreas Reimold10, Joshua Baker11, Geoffrey Thiele1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC Department of Rheumatology, Omaha, NE, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6University of Pittsburgh, Pittsburgh, PA, 7Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 8VA Boston Healthcare System, Boston, MA, 9Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 10Dallas VA Medical Center, Dallas, TX, 11University of Pennsylvania, Philadelphia, PA

    Background/Purpose: There exists a need to identify informative peripheral blood biomarkers for RA-interstitial lung disease (RA-ILD) and elucidate the pathophysiological processes driving RA-ILD onset. Several…
  • Abstract Number: 1810 • ACR Convergence 2025

    Destabilized Treg Cells Predominant in Severe Forms of Juvenile Idiopathic Arthritis

    Ki Pui Lam1, Claudia Harris2, Jennifer Cheng3, Lwiza AitDowd4, Maryam Ashoor5, Ahmad Bakhsh3, Carrie Bryant3, Siobhan Case6, Mia Chandler3, Joyce Chang3, Ezra Cohen7, Fatma Dedeoglu3, Olha Halyabar8, Jonathan Hausmann9, Melissa Hazen3, Sonia Iosim10, Liyoung Kim11, Jeffrey Lo3, Mindy Lo3, Emma Materne3, Esra Meidan12, Megan Perron13, Helene Powers10, Mary Beth Son3, Holly Wobma3, Margaret Chang3, Pui Lee14, Peter Nigrovic11 and Lauren Henderson15, 1Division of Immunology, Boston Childrens Hospital, Harvard Medical School, Boston, MA, 2Division of Immunology, Boston Childrens Hospital, Boston, MA, 3Boston Children's Hospital, Boston, MA, 4Boston Children's Hospital, Harvard Medical School, Boston, MA, 5Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Brookline, MA, 6UpToDate, Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, 7Bmc, NEEDHAM, MA, 8Children's Hospital/Boston Medical Center, Newton, MA, 9Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, 10Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, 11Boston Children's Hospital, Brookline, MA, 12Boston Children's Hospital, Somerville, MA, 13Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Natick, MA, 14Boston Children's Hospital, Newton, MA, 15Boston Children's Hospital, Watertown, MA

    Background/Purpose: T peripheral helper (Tph) cells stimulate excessive B cell responses in the joints of patients with autoantibody-positive arthritis, including seropositive RA in adults and…
  • Abstract Number: 1793 • ACR Convergence 2025

    Sex-associated changes to synovial macrophages in the aging joint

    Matthew Dapas1, Erica De Jong2, Yidan Wang3, Cally Mills3, Samuel Dowling4, Tyler Therron5, Carla Marie Cuda3, Dawn Bowdish6 and Deborah Rachelle Winter7, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2McMaster Immunology Research Centre, Hamilton, ON, Canada, 3Northwestern University, Chicago, IL, 4Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 5Northwestern Feinberg School of Medicine, Chicago, IL, 6McMaster University, Hamilton, ON, Canada, 7Northwestern University, Skokie, IL

    Background/Purpose: Macrophages are found in nearly every tissue of the body where they maintain homeostasis and drive healthy immune response. However, macrophages are dysregulated with…
  • Abstract Number: 1528 • ACR Convergence 2025

    Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus

    Esteban C. Garza-Gonzalez1, Fernanda M. Garcia-Garcia2, Oscar Azael Garza-Flores3, Rebeca L. Polina-Lugo4, Leslie Y. Lopez-Cantú2, Jose R Azpiri-Lopez5, Iris J. Colunga-Pedraza2, Jesus Alberto Cardenas-de la Garza6, Dionicio A. Galarza-Delgado2 and Diego Azamat Salcedo Almanza7, 1Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, 2Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, 4Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 5Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 6Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, 7Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disease associated with increased morbidity and mortality, particularly due to cardiovascular complications. Atherosclerotic cardiovascular disease…
  • Abstract Number: 1830 • ACR Convergence 2025

    Single-Cell and Spatial Profiling Reveal Proinflammatory and Profibrotic Fibroblast-Macrophage Niches in Lupus Nephritis

    Chirag Raparia1, Paul Hoover2, Nir Hacohen3, Arnon Arazi4 and Anne Davidson1, 1Feinstein Institutes for Medical Research, Manhasset, NY, 2Brigham and Women's Hospital, Boston, MA, 3Broad Institute of MIT Harvard, Cambridge, MA, 4Feinstein Institutes for Medical Research, Acton, MA

    Background/Purpose: Lupus nephritis (LN) is a severe complication of SLE that can progress to chronic kidney disease, renal fibrosis, and eventual renal failure. Fibroblasts activated…
  • Abstract Number: 1722 • ACR Convergence 2025

    Defining Safe Hydroxychloroquine Blood Levels: Time to Switch to Precision Monitoring for Optimized Lupus Care

    Shivani Garg1, Benoit Blanchet2, Yann Nguyen3, Fauzia Hollnagel4, Ada Clarke5, Michelle Petri6, Murray Urowitz7, John Hanly8, Caroline Gordon9, Sang-Cheol Bae10, Juanita Romero-Diaz11, Jorge Sanchez-Guerrero12, Ann Clarke13, Sasha Bernatsky14, Daniel Wallace15, David A. Isenberg16, Anisur Rahman16, Joan Merrill17, Paul Fortin18, Dafna D. Gladman19, Ian Bruce20, Ellen Ginzler21, Mary Anne Dooley22, Rosalind Ramsey-Goldman23, Susan Manzi24, Andreas Jönsen25, Graciela Alarcón26, Ronald van Vollenhoven27, Cynthia Aranow28, Murat Inanc29, Meghan mackay30, Guillermo Ruiz-Irastorza31, S. Sam Lim32, Murat Inac33, Kenneth Kalunian34, Søren Jacobsen35, Christine Peschken11, Diane Kamen36, Anca Askanase37, Jill Buyon38, Julie Chezel5, Alicja Puszkiel39 and Nathalie Costedoat-Chalumeau40, 1University of Madison, School of Medicine and Public Health, Madison, WI, 2National Referral Centre for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Paris, France, 3Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, 4University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, 5Cochin Hospital, Paris, France, 6Johns Hopkins University School of Medicine, Timonium, MD, 7University of Toronto, Toronto, ON, Canada, 8Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, 9Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, 10Hanyang University Medical Center, Seoul, South Korea, 11University of Manitoba, Winnipeg, MB, Canada, 12Mount Sinai Hospital and University Health Network, Toronto, Canada, 13Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 14Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 15Cedars Sinai Medical Center, Studio City, CA, 16University College London, London, United Kingdom, 17Oklahoma Medical Research Foundation, Oklahoma, 18Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 19Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, 20Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom, 21SUNY Downstate Health Sciences University, New York, NY, 22UNC physician network, Chapel Hill, NC, 23Northwestern University Feinberg School of Medicine, Chicago, IL, 24Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, 25Department of Clinical Sciences, Lund University, Lund, Sweden, 26The University of Alabama at Birmingham, Oakland, CA, 27Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, 28Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, 29Istanbul University, Istanbul, Turkey, 30Feinstein Institutes for Medical Research, Manhasset, NY, 31Biobizkaia Health Research Institute, Barakaldo, Spain, 32Emory University School of Medicine, Atlanta, GA, 33Istanbul University, Istanbul, 34UC San Diego, La Jolla, CA, 35Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 36Medical University of South Carolina, Johns Island, SC, 37Columbia University Medical Center, New York, NY, 38NYU Grossman School of Medicine, New York, NY, 39Cochin Hospital, Paris, 40Inserm DR Paris 5, Paris, France

    Background/Purpose: Current guidelines recommend using hydroxychloroquine (HCQ) dose ≤5.0 mg/kg for managing SLE. However, 6-fold higher SLE flares, including those requiring hospitalizations, are noted with…
  • Abstract Number: 1573 • ACR Convergence 2025

    Health-related quality of life over 15 years in systemic sclerosis: impact of sex and survival

    Katherine van der Wouden1, Georgy Gomon2, Rachel Knevel2, Michel Tsang-A-Sjoe3, Alexandre Voskuijl3 and Jeska de Vries-Bouwstra2, 1Leiden University Medical Center and Amsterdam University Medical Center, Leiden, Zuid-Holland, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Amsterdam University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Patients with systemic sclerosis (SSc) face an uncertain long‑term outlook; understanding how their health‑related quality of life (HRQoL) changes over time can help them…
  • Abstract Number: 1588 • ACR Convergence 2025

    Prevalence Of Oral Manifestations And Their Association With Clinical And Serological Profile In Systemic Sclerosis Patients- An Indian Study

    Vijaya prasanna Parimi1, Tejaswini Ramineni2, Pradeep S Anand3, Vineeta Shobha4, Padmanabha Shenoy5, Geetabali Sircar6, kaushik Basu7, Anna C Das4, Geetha Amritrao Kale4, indranil sarkar8, Shinie Razil Goveas4, Biswarup Sengupta8, Caseena Kareem9, Yogananth Sakthivel4, Soma Halder Biswas7 and Neel Nallulwar8, 1ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India, 2Esic Medical College And Hospital, Sanathnagar, Hyderabad, Telangana, India, 3ESIC MEDICAL COLLEGE AND HOSPITAL, HYDERABAD, Telangana, India, 4St. John's Medical College Hospital, Bangalore, Bangalore, Karnataka, India, 5Shenoy's CARE, Kochi, Kerala, India, 6West Bengal Medical Education Service, Kolkata, West Bengal, India, 7Medical College, Kolkata, kolkata, West Bengal, India, 8IPGMER, Kolkata, kolkata, West Bengal, India, 9CARE, Kochi, kochi, Kerala, India

    Background/Purpose: Systemic sclerosis (SSC) is a chronic, multisystem autoimmune disease characterized by immune dysfunction, microangiopathy, and tissue remodelling. Orofacial manifestations, including xerostomia, microstomia, tooth decay,…
  • Abstract Number: 1774 • ACR Convergence 2025

    Citrullinated and Malondialdehyde-Acetaldehyde Co-Modified Fibrinogen Activates Macrophages and Induces Pro-Fibrotic shift in Coronary Endothelium Phenotype

    Nozima Aripova1, Wenxian Zhou2, Hannah Johnson1, Michael Duryee1, Kimberley Sinanan1, Carlos Hunter1, Tate Johnson1, Mabruka Alfaidi1, Daniel Anderson3, Kishore Bidasee1, Geoffrey Thiele1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Bellevue, NE, 30587964, Durham, NC

    Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk for developing heart failure with preserved ejection fraction (HFpEF), which is characterized by impaired left ventricular…
  • Abstract Number: 1538 • ACR Convergence 2025

    Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277

    Minoru Hasegawa1, Jun Kinoshita2, Shigeki Otsubo3, Kana Yamada3 and Ehsanollah Esfandiari4, 1Division of Medicine, University of Fukui, Yoshida-gun, Fukui, Japan, 2Kyowa Kirin Co., Ltd., Chiyoda-ku, Tokyo, Japan, 3Kyowa Kirin Co., Ltd., Tokyo, Japan, 4Kyowa kirin International plc, London, United Kingdom

    Background/Purpose: Plasmacytoid dendritic cells (pDCs) are known to be the main source of type 1 interferon (IFN), which is the cause of various autoimmune diseases.…
  • Abstract Number: 1822 • ACR Convergence 2025

    The Circulating Immune Profile of Systemic JIA Patients with HLA-DRB1*15 alleles, Eosinophilia, and Lung Disease

    Jennifer Cheng1, Alexandra Pommier2, Ki Pui Lam3, Evan Hsu4, Courtney Leson5, Kyle McBrearty1, Itohan Aigbekaen1, Maryam Ashoor6, Ahmad Bakhsh1, Carrie Bryant1, Siobhan Case7, Mia Chandler1, Margaret Chang1, Ezra Cohen8, Fatma Dedeoglu1, Olha Halyabar9, Jonathan Hausmann10, Melissa Hazen1, Sonia Iosim1, Liyoung Kim6, Jeffrey Lo1, Mindy Lo1, Emma Materne1, Esra Meidan11, Megan Perron12, Helene Powers13, Mary Beth Son1, Holly Wobma1, Peter Nigrovic6, Alicia Casey1, Joyce Chang1, Pui Lee4 and Lauren Henderson14, 1Boston Children's Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Division of Immunology, Boston Childrens Hospital, Harvard Medical School, Boston, MA, 4Boston Children's Hospital, Newton, MA, 5Boston Children's Hospital, Boston, 6Boston Children's Hospital, Brookline, MA, 7UpToDate, Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, 8Bmc, NEEDHAM, MA, 9Children's Hospital/Boston Medical Center, Newton, MA, 10Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, 11Boston Children's Hospital, Somerville, MA, 12Boston Children's Hospital, Natick, MA, 13Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, 14Boston Children's Hospital, Watertown, MA

    Background/Purpose: We aimed to explore the association between HLA-DRB1*15 alleles, eosinophilia, and lung disease (LD) in patients with systemic juvenile idiopathic arthritis (sJIA) through proteomic…
  • Abstract Number: 1725 • ACR Convergence 2025

    Functional NOTCH4 Variants Drive Vasculopathy and Fibrosis in Systemic Sclerosis.

    U. Kaundal: None; P. Tsou: None; M. Sahu: None; M. Huang: None; S. Boyden: None; C. Woodford: None; D. Shriner: None; S. Safran: None; Y. Zhou: None; X. Zhang: None; Y. Kunishita: None; A. Shah: None; M. Mayes: Argenx, 2, AstraZeneca, 5, atyr, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 1, 5, h, 5, Novartis, 2, prometheus merck, 5; A. Doumatey: None; A. Bentley: None; R. Domsic: None; T. Medsger, Jr: None; P. Ramos: None; R. Silver: None; V. Steen: None; J. Varga: None; V. Hsu: None; L. Saketkoo: Abbvie, 6, Argenx, 1, 2, 5, aTyr Pharmaceuticals, 12,, 1, 5, Boehringer-Ingelheim, 2, 5, 6, CSL Behring, 5, EMD Serono, 2, 5, Horizon, 5, Johnson & Johnson, 6, Kadmon, 5, Kinevant, 12,, 2, 5, Mallinckrodt, 1, 2, 5, Novartis, 1, 2, 5, Priovant, 5; E. Schiopu: None; J. Gordon: Cumberland, 5, Prometheus/Merck, 5; L. Criswell: None; H. Gladue: None; C. Derk: None; E. Bernstein: AstraZeneca, 5, aTYR, 5, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 5, Cabaletta Bio, 5, Synthekine, 2; S. Bridges: None; V. Shanmugam: None; L. Chung: AbbVie/Abbott, 1, Boehringer-Ingelheim, 1, CRISPR Therpeutics, 2, Cure Ventures, 2, jade, 2, Kyverna, 6, Mediar, 1, 2; S. Kafaja: None; M. TROJANOWSKI: None; B. Korman: None; J. Thomas: None; S. Dell'orso: None; d. Randazzo: None; A. Adeyemo: None; E. Remmers: None; P. Schwartzberg: None; I. Aksentijevich: In Vitro Diagnostics, 9; C. Rotimi: None; F. Wigley: None; R. Wang: None; F. Boin: Adicet Bio, 2, Boehringer Ingelheim, 1, Janssen Pharmaceuticals, 6; D. Khanna: Argenx, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Novartis, 2, UCB, 2, Zura Bio, 2; R. Lafyatis: AbbVie/Abbott, 2, Advarra/GSK, 12, Independent Data Safety Monitoring Committees, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, 5, EMD Sereno, 2, Formation, 2, 5, Genentech, 12, Independent Data Safety Monitoring Committees, Genentech/Roche, 2, Mediar, 2, Merck/MSD, 2, Moderna, 5, Modumac Therapeutics Inc., 12, President and holds stock, Morphic, 2, Pfizer, 5, Regeneron, 5, Sanofi, 2, Third Rock Ventures, 2, Thirona Bio, 2, Zag Bio, 2; D. Kastner: In Vitro Diagnostics, 12, NIH Licensing Agreement; P. Gourh: None; E. Stenson: None; T. Talley: None; K. Gudapati: None; J. Wong: None; R. Jan: None; A. Goldberg: None; J. Mullikin: None.

    Background/Purpose: Systemic sclerosis (SSc) is characterized by vasculopathy, progressive fibrosis of skin and internal organs, and autoimmunity. Notably, African American (AA) patients with SSc exhibit…
  • Abstract Number: 1530 • ACR Convergence 2025

    The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus

    Guillermo Pons-Estel1, Rosana Quintana1, Romina Nieto1, Hermine Brunner2, Marina Scolnik3, Carmen Funes Soaje4, Paula Alba5, Veronica Saurit6, Mercedes Garcia7, GUILLERMO ARIEL BERBOTTO8, Inés Verónica Bellomio9, Mario Eduardo Kerzberg10, Graciela Gomez11, Cecilia Pisoni12, Vicente Juarez13, Ana Malvar14, Nélzio Silva15, ODIRLEI MONTICIELO16, Henrique Mariz17, Francinne Ribeiro18, Eduardo Borba19, Eloisa Bonfa19, Edgard Torres dos Reis-Neto20, Iris Guerra Herrera21, Maria Loreto Massardo22, Gustavo Aroca-Martínez23, Lorena Gómez Escorcia24, Carlos Alberto Cañas25, Gerardo Quintana-Lopez26, Carlos Toro-Gutierrez27, Mario Moreno Alvarez28, MIGUEL SAAVEDRA29, Margarita Portela Hernández30, Hilda Fragoso-Loyo31, Luis H Silveira32, Ignacio García-De la Torre33, Carlos Abud-Mendoza34, Jorge Antonio Esquivel Valerio35, Maria Isabel Acosta36, Astrid Paats37, Claudia S. Mora-Trujillo38, Manuel Ugarte-Gil39, Armando Calvo40, Roberto Muñoz-Louis41, Martin Rebella42, Alvaro Danza43, Federico Zazzetti44, Ashley Orillion45, Urbano Sbarigia46 and Bernardo A. Pons-Estel47, 1Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, 4Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 5Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 6Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, 7Hospital Interzonal General de Agudos “General San Martín” de la plata, La Plata, Argentina, 8Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, 9Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, 10Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, 11Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, 12CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, 13Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, 14Organización Médica de Investigación, Buenos Aires, Argentina, 15Hospital das Clinicas da Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, 16Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, 17Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, 18Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio De Janeiro, Rio de Janeiro, Brazil, 19Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 20Universidad Federal São Paulo, São Paulo, Brazil, São Paulo, Brazil, 21Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, 22Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, 23Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, 24Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, 25Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, 26Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, 27Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, 28Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, 29Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, 30Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, 31Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 32Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, 33Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Jalisco, Mexico, 34Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, 35Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, 36Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, 37Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, 38Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, 39Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 40Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, 41Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, 42Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, 43Médica Uruguaya, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, 44Johnson & Johnson, Horsham, PA, USA, Ambler, PA, 45Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 46Johnson & Johnson, Beerse, Belgium, 47Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina

    Background/Purpose: Effective, non-invasive disease activity and treatment response assessments are needed for patients with systemic lupus erythematosus (SLE), especially if associated with kidney disease, i.e.…
  • « Previous Page
  • 1
  • …
  • 125
  • 126
  • 127
  • 128
  • 129
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology